Pharmaceutical composition for treatment of increased intraocular pressure
AssigneeNovaliq GmbH
InventorsBastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
Life of this patent
Estimating the term…
Abstract
The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
Claims23
1-15. (canceled)
A pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a poorly water-soluble prostaglandin analogue, and
- (b) a liquid vehicle comprising a semifluorinated alkane;
- wherein the composition is microbiologically stable, and
- wherein the composition is substantially free of water and free of a preservative, and
- wherein the composition is formulated as a solution, emulsion or suspension.
A method for the prevention or treatment of an eye disease or disorder characterized by increased intraocular pressure, comprising the step of administering a pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a poorly water-soluble prostaglandin analogue, and
- (b) a liquid vehicle comprising a semifluorinated alkane,
- into the eye of a patient.
A pharmaceutical kit comprising a pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a poorly water-soluble prostaglandin analogue, and
- (b) a liquid vehicle comprising a semifluorinated alkane;
- and a container holding the composition.
Dependencies are inferred from the claim text.